This report was first published by Endpoints News. To see the original version, click here
The centerpiece of Sanofi’s immunology efforts succeeded in two more Phase 3 eczema studies in the US, the company announced Friday, setting up a possible FDA submission before the end of the year.
But the program, known as amlitelimab, once again appeared to underperform market leader Dupixent on a measurement of skin clearance, potentially muddying the outlook. And in one of the trials, amlitelimab did not reach statistical significance on the EU-specific primary endpoints.
您已阅读17%（569字），剩余83%（2701字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。